$330M Oversubscribed: Ollin’s Faricimab Challenger Just Became the Most Funded Retinal Disease Bet of 2026
Ollin Biosciences closed an oversubscribed $330M Series B on June 24 to run global Phase 3 trials of OLN324...
Series B Financing
Ollin Biosciences closed an oversubscribed $330M Series B on June 24 to run global Phase 3 trials of OLN324...